(EVGN) Evogene Ltd. Business Model Canvas Research

Canonic Ltd., Evogene Ltd.'s subsidiary, works with Cannbit Ltd. on medical cannabis products, giving Evogene a route into regulated consumer and healthcare-adjacent markets beyond agriculture. The deal supports product development and commercialization in cannabis-based offerings; Evogene has not disclosed a 2025/2026 revenue split for this partnership.

• Expands into regulated cannabis products
• Supports product development
• Supports commercialization

Evogene’s global commercialization partners span the United States, Israel, Brazil, and other markets, giving the Company 3 core geographic bridges to move research into market-ready programs. These ties help Evogene scale across multiple life-science sectors by sharing development risk, speeding validation, and opening local channels for product launch.

• 3 core geographies: U.S., Israel, Brazil
• Moves discoveries into market programs
• Supports multi-sector scaling

Evogene Ltd. uses its discovery platform to R&D seed traits, crop chemicals, and biologicals for five major crops: corn, soybean, wheat, rice, and cotton. The goal is higher yields and better farm performance, which matters in a global crop input market that tops $250 billion a year.

• Seed traits, chemicals, and biologicals
• Focus on 5 major crops
• Aim: higher yields and farm performance

Evogene Ltd. develops microbiome-based human health programs across immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections, while Canonic Ltd. extends the same platform into medical cannabis products. The activity is built around drug discovery and product development, with value tied to pipeline progress and partner-ready assets.

• Microbiome-based health programs
• Immuno-oncology and GI focus
• AMR infection solutions
• Canonic cannabis innovation

Evogene Ltd. runs its resource base through three core divisions" Agriculture, Human Health, and Industrial Applications" plus Canonic Ltd., which adds a dedicated medical cannabis asset. This setup lets the company split capital and know-how across four innovation tracks at once, so one platform can serve more than one market.

• Three operating divisions
• One dedicated Canonic asset
• Four parallel innovation tracks

Evogene Ltd.'s global operating footprint spans the United States, Israel, Brazil, and other markets, with Rehovot, Israel as its main base. That reach matters: it gives the Company direct access to partners and customers across key agri-tech regions, supporting market development and faster local execution.

• Core base: Rehovot, Israel
• Active in the United States and Brazil
• Supports partner access across regions
• Helps grow international market reach

Evogene’s human-health microbiome programs target precision medicine in immuno-oncology, gastrointestinal disease, and antimicrobial-resistant infections. The value lies in pairing strain-level biology with a large unmet need: AMR causes about 1.27 million deaths a year, and the global microbiome therapeutics market is still early, with few approved products.

• Focus: microbiome-based treatments
• Targets: cancer, GI, AMR infections
• Edge: precision-health positioning

Evogene’s partner-ready discovery platform is built to produce candidates that fit licensing or co-development deals, so large pharma and ag players can plug into the pipeline fast. That model makes the platform more attractive to established commercial partners because it lowers early R&D risk and keeps deal options open.

• Built for licensing and co-development
• Targets large industry partners

Evogene Ltd. keeps customer ties project-based, with many deals built around specific R&D programs. That model sets clear milestones and joint technical reviews, so partners can shape scope, data needs, and timelines to fit their own research goals.

• Milestone-led R&D programs
• Shared technical review cadence
• Flexible partner-specific setup

Canonic handles partner support at the subsidiary level, so Evogene Ltd can keep focused, sector-specific ties in medical cannabis while the parent keeps building its broader platform. Evogene Ltd runs 3 main subsidiaries, and this split helps keep customer work close to the use case without losing group-level alignment.

• Focused support for medical cannabis partners
• Subsidiary-level service, parent-level strategy
• Fits Evogene Ltd’s 3-subsidiary structure

Evogene uses the United States, Israel, Brazil, and other markets as business-development and commercialization channels, giving it reach into at least 3 core geographies plus additional local markets. This footprint widens access to industry partners and shortens the path from product validation to market entry.

• U.S., Israel, Brazil focus
• Drives partner access
• Supports local commercialization

Evogene Ltd. uses partner-led market access to let BASF, Corteva, and Bayer move products into growers’ hands faster, while Evogene keeps its own sales footprint light. That matters because BASF, Corteva, and Bayer had 2024 revenues of about €68.9bn, $16.9bn, and €46.6bn, respectively, giving Evogene reach that would be costly to build alone.

• Leans on global agrochemical reach
• Speeds market entry through partners
• Lowers direct distribution cost

Evogene’s human health segment serves biotech and life-science companies building microbiome-based therapies for immuno-oncology and infectious disease. It fits early-stage teams that need computational discovery and pipeline generation; the field is still thin, with just 2 FDA-approved microbiome products in 2023, so fast target finding matters.

• Biotech and life-science customers
• Microbiome therapy pipelines
• Immuno-oncology and infection focus
• Computational discovery first

Evogene Ltd. reaches the medical cannabis segment through Canonic and Cannbit, which link it to regulated product development and commercialization customers. This base is specialized and smaller than consumer cannabis, but it is tied to prescription-grade genetics, consistency, and compliance.

• Canonic: product development
• Cannbit: commercialization
• Regulated, specialized buyers

That mix makes customer demand more technical and higher-touch than in unregulated cannabis markets.

Evogene Ltd. runs a B2B innovation model, so partnership and collaboration costs sit in program management, legal review, and governance for licensing and co-development deals. These costs are not just overhead: they shape how fast Evogene can move research into signed alliances and shared IP.

In 2025 filings, Evogene said its focus remained on technology partnerships across its platform companies, which keeps transaction costs tied to each new agreement. A simple read: more co-development deals mean more coordination, more contract work, and more control checks.

• Coordination drives project overhead
• Legal work protects IP and terms
• Governance adds deal-level costs

Evogene Ltd. faces rising regulatory and commercialization costs as human health and cannabis programs move from discovery to launch. These spend lines cover compliance, filings, trials, market access, and sales setup, and they usually jump sharply in late-stage programs; for example, a single FDA-related pathway can add millions of dollars before first revenue.

• Compliance costs rise with each stage.
• Launch prep adds sales and marketing spend.
• Cannabis and health need stricter review.

Canonic and Cannbit-related activity can generate direct sales from medical cannabis, unlike Evogene Ltd.’s platform-licensing model. That adds a product-based revenue stream, so Evogene Ltd. can earn from cannabis offerings as well as from IP and tech deals. FY2025 filings indicate this is still an early-stage, non-core source.

• Direct cannabis product sales
• Separate from licensing fees
• Early-stage revenue stream

Evogene Ltd. can earn future royalties if partnered programs reach market, so upside scales with commercial success, not just research spend. In life-science licensing, royalty-like rates often run about 2% to 8% of net sales, which can turn one hit product into durable revenue.

For Evogene, that means low current cash cost today, but meaningful downstream economics later. Royalty streams can also outlast the first product launch if a partner expands into new uses or geographies.

• Value rises at commercialization
• Royalties link pay to sales
• One success can compound returns